Meeting
2017 ASCO Annual Meeting
Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer.
Authors
Noah Federman
University of California, Los Angeles, Los Angeles, CA
Noah Federman , Catherine Michelle Albert , Brian Turpin , Leo Mascarenhas , Ramamoorthy Nagasubramanian , Birgit Geoerger , Michela Casanova , Maria Soledad Gallego Melcon , Julia Chisholm , Cornelis M. Van Tilburg , Neerav Narendra Shukla , Sheri L. Spunt , Michael Craig Cox , Douglas S. Hawkins , Alberto S. Pappo , Stefan S. Bielack , Francois P. Doz , Gianni Bisogno , Theodore Willis Laetsch , Steven G. DuBois
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02637687
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS10577)
DOI
10.1200/JCO.2017.35.15_suppl.TPS10577
Abstract #
TPS10577
Poster Bd #
333b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
First Author: Leo Mascarenhas
Poster
2022 ASCO Annual Meeting
Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors.
First Author: Sébastien Perreault
Poster
2019 ASCO Annual Meeting
First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma.
First Author: Vincent Chung
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong